Patents by Inventor Gundo Diedrich

Gundo Diedrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150175701
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Application
    Filed: December 4, 2014
    Publication date: June 25, 2015
    Applicant: diaDexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Publication number: 20140370523
    Abstract: Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.
    Type: Application
    Filed: July 2, 2014
    Publication date: December 18, 2014
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Patent number: 8906369
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: December 9, 2014
    Assignee: diaDexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Publication number: 20130232589
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Application
    Filed: April 24, 2013
    Publication date: September 5, 2013
    Applicant: diaDexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Patent number: 8444971
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: May 21, 2013
    Assignee: Diadexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Patent number: 8354508
    Abstract: The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: January 15, 2013
    Assignee: Diadexus, Inc.
    Inventors: Gundo Diedrich, Paul Levi Miller, Jackie Papkoff, Astrid Strelow
  • Patent number: 8349574
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: January 8, 2013
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Stephen J. Williams
  • Publication number: 20100233732
    Abstract: Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.
    Type: Application
    Filed: January 15, 2010
    Publication date: September 16, 2010
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Publication number: 20100210034
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Application
    Filed: January 15, 2010
    Publication date: August 19, 2010
    Applicant: LABORATORY CORPORATION OF AMERICA HOLDINGS
    Inventors: MICHAEL BATES, ALI MUKHERJEE, GORDON PARRY, JEFF SPERINDE, JENNIFER W. COOK, GUNDO DIEDRICH, LAURIE GOODMAN, STEPHEN J. WILLIAMS
  • Publication number: 20100150907
    Abstract: The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.
    Type: Application
    Filed: July 20, 2007
    Publication date: June 17, 2010
    Applicant: DIADEXUS, INC.
    Inventors: Gundo Diedrich, Paul Levi Miller, Jackie Papkoff, Astrid Strelow
  • Publication number: 20100136009
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovrl 10 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovrl 10-expressing cancer cells and alleviating or treating an Ovrl 10-expressing cancer in a mammal. The anti-Ovrl 10 antibodies modulate Ovrl 10 function or internalize upon binding to Ovrl 10 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovrl 10 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovrl 10 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Application
    Filed: November 27, 2007
    Publication date: June 3, 2010
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Publication number: 20100074893
    Abstract: The invention provides isolated anti-ECM-complex antibodies that bind to ECM-complexes. The invention also encompasses compositions comprising an anti-ECM-complex antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-ECM-complex antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-ECM-complex antibodies. The invention encompasses a method of producing the anti-ECM-complex antibodies. Other aspects of the invention are a method of detecting an ECM-complex expressing cancer, a method of inhibiting growth of an ECM-complex-expressing tumor, and a method of alleviating or treating an ECM-complex-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-ECM-complex antibody to the mammal.
    Type: Application
    Filed: April 10, 2009
    Publication date: March 25, 2010
    Inventors: Annette Bistrup, Gundo Diedrich, Paul Levi Miller